Divi's Laboratories (DIVISLAB.NS) Azione Prezzo
Divi's Laboratories Prezzo
Negli ultimi 19 anni Divi's Laboratories ha aumentato il fatturato del 18,4% all'anno, raggiungendo 93,60 miliardi INR. L'utile per azione è cresciuto del 19,8% all'anno negli ultimi 19 anni. Per Divi's Laboratories, il margine netto del 23,4% risulta in calo rispetto al 28,5% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 0,32%. Il payout ratio è pari a circa il 36% degli utili. Il dividendo è cresciuto del 24,0% all'anno negli ultimi 19 anni. Il target di prezzo di consenso a 12 mesi per Divi's Laboratories è 7012,50 INR, circa il 26,2% sotto il prezzo attuale di mercato. Su 36 analisti, 20 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Divi's Laboratories Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Divi's Laboratories Azione e analisi azionaria
Domande frequenti sull'azione Divi's Laboratories
The business model of Divi's Laboratories Ltd revolves around the manufacture and supply of active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies worldwide. With a focus on quality, innovation, and cost-effective production, Divi's Labs caters to a wide range of therapeutic segments including generics, custom synthesis, and development of new molecules. By leveraging its strong research and development capabilities, cutting-edge technology, and state-of-the-art manufacturing facilities, Divi's Labs has established itself as a trusted supplier in the global pharmaceutical industry.
Divi's Laboratories Ltd is primarily active in the pharmaceutical industry.
The main competitors of Divi's Laboratories Ltd in the market include Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, and Cipla Ltd.
Divi's Laboratories Ltd is an Indian pharmaceutical company that was founded in 1990. It is headquartered in Hyderabad, Telangana. The company specializes in the research, development, and manufacturing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Divi's Laboratories has a strong focus on quality with a global customer base and is recognized for its state-of-the-art manufacturing facilities. Over the years, the company has consistently grown and expanded its product portfolio. Divi's Laboratories is committed to innovation, research, and delivering high-quality healthcare solutions to meet the needs of patients worldwide.
Divi's Laboratories Ltd has achieved numerous significant milestones throughout its journey. Notably, the company has consistently demonstrated excellence in the pharmaceutical sector since its establishment. Divi's Laboratories Ltd has successfully garnered a strong reputation for its high-quality manufacturing practices and commitment to innovation. The company has also gained several certifications, including ISO 9001, ISO 14001, and OHSAS 18001, further solidifying its credibility. Moreover, Divi's Laboratories Ltd has expanded its operations globally, establishing a strong presence in various international markets. These incredible achievements highlight Divi's Laboratories Ltd's unwavering dedication to delivering exceptional pharmaceutical solutions while maintaining the highest standards of quality and compliance.
Divi's Laboratories Ltd is primarily present in India, with its headquarters located in Hyderabad. The company operates multiple manufacturing facilities in different locations across India, including Visakhapatnam, Hyderabad, and Mahad. Divi's Laboratories Ltd focuses on manufacturing and supplying active pharmaceutical ingredients (APIs) and intermediates globally. It has a strong presence in various countries and regions, including the United States, Europe, Japan, Korea, and several emerging markets. With its commitment to quality and adherence to international regulatory standards, Divi's Laboratories Ltd has established itself as a trusted supplier of pharmaceutical products worldwide.
Divi's Laboratories Ltd is committed to upholding values of excellence, integrity, and innovation. With a strong corporate philosophy centered around quality and customer satisfaction, the company continually strives to provide top-notch pharmaceutical products and services. Divi's Laboratories Ltd focuses on research and development to ensure cutting-edge solutions and advancements in the field. The company's emphasis on ethical practices and transparency reflects its commitment to maintaining strong relationships with stakeholders. Divi's Laboratories Ltd's dedication to continuous improvement and market leadership makes it a preferred choice for investors seeking a reliable and progressive pharmaceutical company.
Gli analisti fissano attualmente un prezzo obiettivo medio di 6987,18 INR per l’azione Divi's Laboratories (mediana: 7012,50 INR), pari a -26,5 % rispetto all’ultimo prezzo. Il consenso si basa su 36 giudizi di analisti.
36 analisti valutano attualmente l’azione Divi's Laboratories: 21 raccomandano l’acquisto, 6 la tenuta e 9 la vendita. Per il 2026 gli analisti si aspettano per Divi's Laboratories ricavi pari a 106,46 miliardi INR e un utile per azione di 115,11 INR.
Convertita al tasso di cambio attuale, l’azione Divi's Laboratories quota 89,31 EUR (9505,50 INR).
L’azione Divi's Laboratories (DIVISLAB.NS) è quotata su 2 borse, tra cui: NSE (Indien) (DIVISLAB.NS).
Divi's Laboratories Ltd is an Indian company that manufactures pharmaceutical active ingredients and intermediates for the global market. The company was founded in 1990 and is headquartered in Hyderabad, India. Divi's Laboratories' business model is based on extensive research and development and high production capacity. The company follows a vertically integrated production strategy, engaging in the development of new active ingredients and the production of intermediates and finished products. Divi's Laboratories serves a variety of industries such as the pharmaceutical and cosmetic industries, agriculture, and the food industry. The company offers a wide range of products such as antibiotics, antidepressants, vitamins, and folic acid for the pharmaceutical industry. For the cosmetic and food industries, the company offers emulsifiers, fragrances and flavors, as well as dyes and sunscreens. The company has two modern manufacturing facilities with a total capacity of over 500 tons per year. Divi's Laboratories continuously invests in state-of-the-art production facilities to increase capacity and productivity. Divi's Laboratories specializes in the manufacture of pharmaceutical active ingredients and intermediates and therefore enjoys a good reputation in the industry. The company has established a strong position in the market in recent years and has expanded into various countries such as the USA, Europe, and Asia. The company is also successful in research and development of new products. Divi's Laboratories has its own research and development department that develops new synthetic methods and processes for the production of active ingredients. The company works closely with customers to produce customized products for their specific requirements. Furthermore, Divi's Laboratories is involved in the research of natural substances that can be used in the medical field. The company has its own department for biotechnological research and development to isolate new natural substances and investigate their potential for medical application. In summary, Divi's Laboratories' business model is very successful and focused on a wide range of products and extensive research and development. The company has established a strong position in the global market for pharmaceutical active ingredients and intermediates and is on track to further expand its position.
Il attesa fatturato di Divi's Laboratories ammonta a 106,46 miliardi INR. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Divi's Laboratories ammonta a 30,53 miliardi INR. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Divi's Laboratories è attualmente 82,58. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Divi's Laboratories.
Il rapporto prezzo/fatturato (P/S) di Divi's Laboratories è attualmente 23,68. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Divi's Laboratories.
Il Quality Score AlleAktien per Divi's Laboratories è 6/10.
L'ISIN di Divi's Laboratories è INE361B01024. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il ticker di Divi's Laboratories è DIVISLAB.NS. Con questo simbolo di borsa vengono negoziate le azioni Divi's Laboratories in borsa.
Azione Divi's Laboratories
Gruppo di pari di Divi's Laboratories
Divi's Laboratories Ticker
Divi's Laboratories FIGI
Altre metriche e analisi di Divi's Laboratories in Deep Dive.
La nostra analisi azionaria dell'azione Divi's Laboratories include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Divi's Laboratories. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: